Protagonist Therapeutics Inc (PTGX)
Quick ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 97,249 | 186,727 | 125,744 | 123,665 | 117,358 |
| Short-term investments | US$ in thousands | 321,664 | 154,890 | 111,611 | 203,235 | 188,451 |
| Receivables | US$ in thousands | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 47,398 | 21,274 | 31,179 | 44,016 | 40,241 |
| Quick ratio | 8.84 | 16.06 | 7.61 | 7.43 | 7.60 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($97,249K
+ $321,664K
+ $—K)
÷ $47,398K
= 8.84
The quick ratio of Protagonist Therapeutics Inc shows a consistently strong liquidity position over the years, well above the benchmark of 1.0. As of December 31, 2020, the quick ratio was 7.60, indicating that the company had $7.60 of liquid assets available to cover each dollar of current liabilities. This ratio remained robust at 7.43 as of December 31, 2021, and 7.61 as of December 31, 2022.
There was a significant increase in the quick ratio to 16.06 as of December 31, 2023, signaling a substantial improvement in the company's ability to meet its short-term obligations with liquid assets. However, this ratio decreased to 8.84 as of December 31, 2024, but still reflects a high level of liquidity.
Overall, the trend indicates that Protagonist Therapeutics Inc has maintained a healthy liquidity position, providing a strong buffer to cover its short-term liabilities, which is a positive sign for the company's financial health and ability to meet its obligations.
Peer comparison
Dec 31, 2024